PHYTOHEALTH CORPORATION

PG2® Plus Chemoradiotherapy Improves Survival in Esophageal Cancer Patients

- A clinical study by PhytoHealth Corporation shows that Astragalus Polysaccharides (PG2®) combined with chemoradiotherapy (CCRT) significantly improves survival in advanced esophageal cancer patients. - Patients receiving PG2® with CCRT had longer overall survival and a higher tumor objective response rate compared to those receiving CCRT alone, indicating enhanced treatment efficacy. - PG2® modulates the tumor immune microenvironment (TIME), strengthens the immune system, and suppresses tumor growth, offering a new approach to esophageal cancer treatment. - The study suggests PG2® can help patients complete cancer treatment by reducing inflammation, improving strength, and mitigating cancer-related fatigue, leading to better therapeutic outcomes.